Aldoxorubicin
Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate in development by CytRx. Specifically, it is the (6- maleimido caproyl) hydrazone of doxorubicin. Essentially, this chemical name describes doxorubicin attached to an acid-sensitive linker (N-ε-maleimidocaproic acid hydrazide, or EMCH). The proposed mechanism of action is as follows: # After administration, aldoxorubicin rapidly binds endogenous circulating albumin through the EMCH linker. # Circulating albumin preferentially accumulates in tumors, bypassing uptake by other non-specific sites including heart, bone marrow and gastrointestinal tract. # Once albumin-bound aldoxorubicin reaches the tumor, the acidic environment of the tumor causes cleavage of the acid sensitive linker. # Free doxorubicin is released at the site of the tumor. Clinical trials Five phase I trials for safety characterization have been completed. Several phase II and III trials are underway. Phase II As of January 2017, there are 6 p ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]